[Prognostic value of 18F-FDG PET-CT in Hodgkin lymphoma].
OBJECTIVE
To determine the predictive value of interim and end-of-treatment ¹⁸F-FDG PET-CT after first-line treatment in patients with Hodgkin lymphoma (HL).


METHODS
The clinical data of 50 newly diagnosed HL patients were retrospectively analyzed. Baseline, interim and end-of-treatment PET-CT were performed, and then imaging results were analyzed for the survival of patients via software SPSS 13.0.


RESULTS
Fifty patients received first-line treatment with ABVD (doxorubicin + bleomycin + vincristine + dacarbazine) or BEACOPP (bleomycin + etoposide + doxorubicin + cyclophosphamide + vincristine + procarbazine+ prednisone) regimen. Interim PET-CT of 35 patients were performed after 2-4 cycles of treatment, 46 patients received PET-CT scans at the end of treatment. After a median follow-up of 29.4 months (12.2-52.4 months), the 3-year progression-free survival (PFS) rates were 100% and 70% for the interim PET-CT negative (n=25) and positive (n=10) patients, respectively (P=0.004). The 3-year PFS rates were 100% and 60% for the post-treatment PET-CT negative (n=36) and positive (n=10) patients, respectively (P<0.01).


CONCLUSIONS
Interim and end-of-treatment PET-CT were correlated with 3-year PFS rates for HL patients. They may play an important role in predicting the outcome of HL. The relationship with OS can not be determined because of the short follow-up time.
Peking University Cancer Hospital & Institute, Department of Lymphoma, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing 100142, China.
Zhitao
Z
Ying
Peking University Cancer Hospital & Institute, Department of Lymphoma, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing 100142, China.
Xuejuan
X
Wang
Peking University Cancer Hospital & Institute, Department of Lymphoma, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing 100142, China.
Yuqin
Y
Song
Peking University Cancer Hospital & Institute, Department of Lymphoma, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing 100142, China.
Wen
W
Zheng
Peking University Cancer Hospital & Institute, Department of Lymphoma, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing 100142, China.
Xiaopei
X
Wang
Peking University Cancer Hospital & Institute, Department of Lymphoma, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing 100142, China.
Yan
Y
Xie
Peking University Cancer Hospital & Institute, Department of Lymphoma, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing 100142, China.
Ningjing
N
Lin
Peking University Cancer Hospital & Institute, Department of Lymphoma, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing 100142, China.
Meifeng
M
Tu
Peking University Cancer Hospital & Institute, Department of Lymphoma, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing 100142, China.
Lingyan
L
Ping
Peking University Cancer Hospital & Institute, Department of Lymphoma, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing 100142, China.
Weiping
W
Liu
Peking University Cancer Hospital & Institute, Department of Lymphoma, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing 100142, China.
Lijuan
L
Deng
Peking University Cancer Hospital & Institute, Department of Lymphoma, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing 100142, China.
Chen
C
Zhang
Peking University Cancer Hospital & Institute, Department of Lymphoma, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing 100142, China.
Zhi
Z
Yang
Peking University Cancer Hospital & Institute, Department of Lymphoma, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing 100142, China.
Jun
J
Zhu
D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D019788:Fluorodeoxyglucose F18; D006689:Hodgkin Disease / Q000000981:diagnostic imaging*; D006801:Humans; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography; D011379:Prognosis; D012189:Retrospective Studies; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D019788:Fluorodeoxyglucose F18